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Background and aims 
Several epidemiological studies highlighted the association between folate and B-vitamins low intake and 
cardiovascular diseases (CVD) risk. Contrasting results were reported on the relationship between folate 
intake and DNA-methylation. Folate and B-vitamins may modulate DNA-methylation of specific enzymes 
which are included in the One-Carbon Metabolism (OCM) and in the homocysteine (Hcy) pathways. The 
aim of the study was to evaluate whether DNA-methylation profiles of OCM and Hcy genes could modulate 
the myocardial infarction (MI) risk conferred by a low B-vitamins intake. 
Methods and results 
Study sample (206 MI cases and 206 matched controls) is a case-control study nested in the prospective 
EPIC cohort. Methylation levels of 33 candidate genes where extracted by the whole epigenome analysis 
(Illumina-HumanMethylation450K-BeadChip). We identified three differentially methylated regions in 
males (TCN2 promoter, CBS 5′UTR, AMT gene-body) and two in females (PON1 gene-body, CBS 5′UTR), 
each of them characterized by an increased methylation in cases. Functional in silico analysis suggested a 
decreased expression in cases. A Recursively Partitioned Mixture Model cluster algorithm identified distinct 
methylation profiles associated to different MI risk: high-risk vs. low-risk methylation profile groups, 
OR = 3.49, p = 1.87 × 10−4 and OR = 3.94, p = 0.0317 in males and females respectively (multivariate 
logistic regression adjusted for classical CVD risk factors). Moreover, a general inverse relationship between 
B-vitamins intake and DNA-methylation of the candidate genes was observed. 
Conclusions 
Our findings support the hypothesis that DNA-methylation patterns in specific regions of OCM and Hcy 
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Introduction 
Cardiovascular diseases (CVD) are the leading cause of mortality, morbidity and hospitalization in both 
genders in Europe and North America [1]. Diabetes mellitus, hypercholesterolemia, smoking, hypertension, 
obesity and physical inactivity are the primary risk factors for these diseases [2] and [3]. Other risk factors 
concur to the etiology such as low socioeconomic status, unhealthy dietary habits, alcohol or drugs abuse, 
lipoproteins, left ventricular hypertrophy. Non-modifiable risk factors include age, male gender, ethnicity 
and family history [4]. 
Several studies focused on the inverse relationship between B-vitamins intake and CVD risk [5]. As an 
example, it is well established that folates and some B-vitamins (B2, B6 and B12, folic acid) introduced with 
diet can reduce serum homocysteine (Hcy) levels promoting its re-methylation to methionine [6], and that 
an elevated plasma Hcy level is an independent risk factor for CVD [7]. 
In humans and in animal models, global decreased DNA-methylation was observed in atherosclerotic 
lesions, a condition linked to low intake of folates, methionine-rich diet, and elevated plasma Hcy levels [8], 
although human supplementation studies reported contrasting results [9] and [10]. DNA-methylation of 
CpG sites in the gene promoter region is an important determinant of gene expression, having an inverse 
relationship [11]. The mechanism by which folate and B-vitamins intake may modulate DNA-methylation 
depends on the activity of specific enzymes, many of which are included in the One Carbon Metabolism 
(OCM) [12]. The OCM is a complex network of biochemical reactions, involving the transfer of one-carbon 
groups needed for DNA-methylation and nucleotide synthesis [13], with the production of several 
metabolic intermediates in the Hcy and folate metabolic pathways. Specifically, in the Hcy pathway the de-
methylation of the methionine-derived s-adenosyl methionine provides methyl groups for DNA-
methylation, and generates S-adenosyl-homocysteine and ultimately Hcy. Folates and B-vitamins play a 
pivotal role as enzymatic co-factors. 
The aim of this study was to investigate the possible role of DNA-methylation of genes in folate-dependent-
OCM and Hcy pathways as a mediator of the CVD risk conferred by a low intake of folates and B-vitamins. 
Methods 
Study sample 
The study sample includes 206 myocardial infarction (MI) cases and 206 matched controls from prospective 
case-control study nested in the EPIC cohort [14]. Details on matching parameters, outcome definition, 
laboratory analysis, methylation measurements, dietary and lifestyle information, and candidate genes 
selection are provided in Supplementary Methods (Text S1). 
Study design 
We first investigated the relationship between candidate genes DNA-methylation levels and folic acid (B9-
vitamin), riboflavin (B2-vitamin), niacin (B3-vitamin), and pyridoxine (B6-vitamin) intake. Then, the 
association between DNA-methylation levels and MI risk was evaluated. Methylation values of CpG located 
in genes resulted significant from previous analyses were used in a cluster algorithm to group subjects with 
similar methylation profiles. Finally, we evaluated the association between the different clusters and MI 
risk using multivariate logistic regression analysis, adjusted for the classical CVD factors. The correlation 
between candidate genes DNA-methylation and gene-expression levels in several tissues was also 
investigated through data mining in publicly available databases. Details on statistical methods are 
provided in Supplementary Methods. 
This study complies with the Declaration of Helsinki principles, and conforms to ethical requirements. All 
volunteers signed an informed consent form at enrollment. The EPIC study protocol was approved by Ethics 
Committees at the International Agency for Research on Cancer (Lyon, France) and at the Human Genetics 
Foundation (Turin, Italy). 
Results 
In the broader context of a genome-wide DNA-methylation analysis performed on 206 MI cases and 206 
matched controls, we selected 33 genes involved in Hcy metabolism and OCM pathways (Table 1), for a 
total of 575 CpG sites. Sample characteristics are reported, according to stratification by gender (Table 2). 
The average follow-up was 12.80 (±2.15) years and 12.23 (±2.53) years for cases and controls 
respectively. The average time between recruitment and MI for cases was 5.98 (±3.58) years. 
Table 1.  
List of candidate genes. 
Gene ID Gene name Gene selection criteria 
AHCY adenosylhomocysteinase 
ahsa00270:Cysteine and methionine 
metabolism 
ALDH1L1 aldehyde dehydrogenase 1 family, member L1 ahsa00670:One carbon pool by folate 
AMT aminomethyltransferase ahsa00670:One carbon pool by folate 
APOE 
apolipoliterature and/or gene function/interaction 
E 





ahsa00670:One carbon pool by folate 
BHMT betaine-homocysteine methyltransferase 
ahsa00270:Cysteine and methionine 
metabolism 
CBL 
Cas-Br-M (murine) ecotropic retroviral 
transforming sequence 
gene function and/or protein–protein 
interaction 
CBS cystathionine-beta-synthase 
ahsa00270:Cysteine and methionine 
metabolism 
CTH cystathionase (cystathionine gamma-lyase) 
ahsa00270:Cysteine and methionine 
metabolism 
DHFR dihydrofolate reductase ahsa00670:One carbon pool by folate 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 
ahsa00270:Cysteine and methionine 
metabolism 
FOLH1 
folate hydrolase (prostate-specific membrane 
antigen) 1 
ahsa00670:One carbon pool by folate 
FOLR1 folate receptor 1 
gene function and/or protein–protein 
interaction 
FOLR2 folate receptor 2 
gene function and/or protein–protein 
interaction 
FTCD formiminotransferase cyclodeaminase 
gene function and/or protein–protein 
interaction 
GART phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
ahsa00670:One carbon pool by folate 
Gene ID Gene name Gene selection criteria 
phosphoribosylaminoimidazole synthetase 
MAT1A methionine adenosyltransferase I, alpha 
ahsa00270:Cysteine and methionine 
metabolism 
MAT2B methionine adenosyltransferase II, beta 




(NADP + dependent) 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthetase 
ahsa00670:One carbon pool by folate 
MTHFD1L 
methylenetetrahydrofolate dehydrogenase 
(NADP + dependent) 1-like 
ahsa00670:One carbon pool by folate 
MTHFD2 
methylenetetrahydrofolate dehydrogenase 
(NADP + dependent) 2, methenyltetrahydrofolate 
cyclohydrolase 
ahsa00670:One carbon pool by folate 
MTHFD2L 
methylenetetrahydrofolate dehydrogenase 
(NADP + dependent) 2-like 













ahsa00270:Cysteine and methionine 
metabolism,ahsa00670:One carbon 




gene function and/or protein–protein 
interaction 
NNMT nicotinamide N-methyltransferase 
gene function and/or protein–protein 
interaction 
PON1 paraoxonase 1 
gene function and/or protein–protein 
interaction 
RFC1 replication factor C (activator 1) 1, 145 kDa 
gene function and/or protein–protein 
interaction 
SHMT1 serine hydroxymethyltransferase 1 (soluble) ahsa00670:One carbon pool by folate 
SHMT2 serine hydroxymethyltransferase 2 (mitochondrial) ahsa00670:One carbon pool by folate 
Gene ID Gene name Gene selection criteria 
TCN2 transcobalamin II; macrocytic anemia 
gene function and/or protein–protein 
interaction 
TYMS thymidylate synthetase ahsa00670:One carbon pool by folate 
a 
KEGG, Kyoto Encyclopedia of Genes and Genomes, Nucleic Acids Res. 2000; 28:27–30. 
 












N = 139 
 
N = 139 
 
N = 67 
 
N = 67 
 
Centre N N Centre N N 
 Turin 87 87  Turin 11 11 
 Varese 38 38  Varese 42 42 
 Ragusa 14 14  Ragusa 3 3 
   
 Naples 11 11 
 Lifestyle variables N % N % Lifestyle variables N % N % 
Smokeb Smokeb 
 Never 36 61% 23 39%  Never 49 61% 31 39% 
 Former 62 56% 48 44%  Former 7 54% 6 46% 
 Current 41 38% 68 62%  Current 11 27% 30 73% 
Coffee (cup/day) Coffee (cup/day)b 
Non drinkers 4 67% 2 33% Non drinkers 4 57% 3 43% 
 (0–2) 33 57% 25 43%  (0–2) 21 72% 8 28% 











N = 139 
 
N = 139 
 
N = 67 
 
N = 67 
 
 (4–5) 15 43% 20 57%  (4–5) 8 42% 11 58% 
 More than 5 22 37% 38 63%  More than 5 2 10% 18 90% 
Alcohol (gr./day)b Alcohol (gr./day) 
 (0–12) 50 45% 61 55%  (0–6) 44 48% 48 52% 
 (12–24) 39 67% 19 33%  (6–12) 5 45% 6 55% 
 More than 24 50 46% 59 54%  More than 12 18 58% 13 42% 
 Anthropometrics Mean ±SD Mean ±SD Anthropometrics Mean ±SD Mean ±SD 
Age (years) 49.88 7.10 49.84 7.17 Age (years) 53.75 8.06 54.06 7.89 
BMI (kg/m2)a 26.36 3.13 27.26 2.95 BMI (kg/m2) 26.51 5.32 27.25 5.09 
WHR (waist-hip 
ratio) 
0.93 0.06 0.94 0.06 
WHR (waist-hip 
ratio)a 
0.80 0.06 0.83 0.06 
Blood Pressure (mm 
Hg)     
Blood Pressure (mm 
Hg)     
 Diastolic 84.96 10.28 85.03 9.05  Diastolic 85.30 8.37 86.75 10.14 
 Systolic 134.96 18.77 135.66 15.23  Systolica 135.90 17.30 145.55 23.50 
Lipids (mg/dL) Lipids (mg/dL) 
 LDL Cholesterola 137.69 39.15 151.40 39.04  LDL Cholesterol 150.37 36.54 160.20 47.68 
 HDL Cholesterola 56.55 13.52 50.54 11.78  HDL Cholesterol 65.73 16.01 61.32 15.53 
 Total Cholesterola 224.23 47.18 235.52 43.50  Total Cholesterol 240.82 41.47 249.72 51.27 
 Triglycerides 149.91 93.21 167.93 90.88  Triglycerides 123.61 51.66 141.01 107.44 
 B vitamins intake 
Folic Acid (μg/die)a 317.11 96.10 288.01 102.10 Folic Acid (μg/die) 284.09 103.82 253.35 94.24 











N = 139 
 
N = 139 
 
N = 67 
 
N = 67 
 
Riboflavin (mg/die) 1.65 0.47 1.61 0.51 Riboflavin (mg/die) 1.60 0.64 1.50 0.54 
Niacin (mg/die) 22.62 6.3 21.29 7.15 Niacin (mg/die) 17.25 5.77 17.00 4.87 
a 
T test p-value < 0.05. 
b 
Chi-squared test p-value < 0.05. 
 
Significant differences between cases and controls were observed for smoking status, alcohol consumption, 
BMI, LDL cholesterol, HDL cholesterol, total cholesterol, folic acid and pyridoxine intake in males; smoking 
status, WHR, systolic pressure and coffee consumption in females. We also ascertained a lower B-vitamins 
intake in cases, both in males and in females (Table 2). 
Interestingly, the methylation status of more than 97% of the examined probes negatively correlated with 
pyridoxine, riboflavin, niacin and folic acid intake both in males and females (data not shown), although 
some correlations were not statistically significant. 
In males, six DMRs were identified in the training set, three of which (TCN2 gene promoter, CBS gene 5′
UTR, AMT gene body; Table 3) were confirmed in the test set (see Supplementary Methods for analysis 
details). In females, four DMRs were identified in the training set, two of which were confirmed in the test 
set (PON1 gene body/1st exon, CBS gene 5′UTR; Table 3). For all these chromosomal regions a negative 
correlation between CpG methylation and B-vitamins intake was observed ( Table S1), as well as a higher 
DNA-methylation in cases vs. controls ( Table S2). 
Table 3.  
Differentially methylated regions in males and females respectively (training-set). Regions which were 
confirmed in the-test set are in bold. 
CHR BP STARTa BP ENDa SIZE n Probes Gene RIb SEb RSb 
Males 
20 32891026 32891428 403 10 AHCY 0.49 0.09 5.47 
1 70876492 70877088 597 11 CTH 0.27 0.06 4.36 
CHR BP STARTa BP ENDa SIZE n Probes Gene RIb SEb RSb 
3 49459855 49460177 323 8 AMT 0.32 0.10 3.31 
21 44480624 44480711 88 3 CBS 0.14 0.05 3.13 
22 31002892 31003283 392 8 TCN2 0.18 0.06 2.92 
21 44494906 44495288 383 5 CBS 0.30 0.10 2.88 
6 151346268 151346409 142 3 MTHFD1L 0.37 0.16 2.37 
Females 
5 78407418 78408347 930 11 BHMT 0.60 0.07 8.17 
7 94953653 94954202 550 9 PON1 0.54 0.08 6.48 
3 49459855 49460177 323 8 AMT 0.46 0.12 3.99 




RI = regulation index of the region indicate the percentage of regulated loci; SE = standard error of 
estimated RI; RS = regulation score defined as RI/SE. 
 
The correlation between gene-expression levels and DNA-methylation profiles of CpGs within the DMRs 
was examined by mining the MENT database (see methods): despite only two of the 30 identified CpGs 
(Table S2) were found in the database, it should be noted that the methylation levels of all the CpGs within 
each of the four identified DMR positively correlate (as tested by pairwise comparisons), and it might be 
expected they likely have the same relationship with gene expression levels. Cg20191453 (AMT gene body) 
showed a strong negative correlation with gene-expression in brain, colon, ovary, and rectum ( Table S3); 
cg07404485 (PON1 gene body) showed a significant inverse relationship with gene-expression in ovary 
only, while no significant result was found for other tissues, although the same trend was clearly observed 
in colon, prostate, and rectum. 
Lastly, the RPMM method identified four clusters in males and five in females based on the DNA-
methylation profiles of the DMRs confirmed in the test set. The estimation of the risk conferred by the 
different methylation profiles was comparable at the three levels of adjustment (without adjustment, 
adjusting for matching variables, adjusting for matching variables and cardiovascular risk factors; Table 4). 
Specifically, focusing on the last model, the OR was 3.49 (95% CI 1.81–6.73; p = 1.87 × 10−4) when 
comparing the two extreme groups in males ( Table 4), and OR = 3.94 (95% CI 1.13–13.75; p = 0.0317) when 
comparing the two extreme groups in females ( Table 4). 
Table 4.  
Multivariate logistic regression analysis in males and females taking the CLUSTER 1 with lower MI risk as 
reference: clusters were identified through RPMM method. 






































Females OR (95% CI)a p OR (95% CI)b p OR (95% CI)c P 
CLUSTER 2 1.75 (0.68–4.49) 0.2455 1.75 (0.68–4.54) 0.2488 1.85 (0.58–5.90) 0.3001 
CLUSTER 3 1.86 (0.54–6.37) 0.3250 1.98 (0.55–7.16) 0.2952 3.00 (0.81–11.05) 0.0995 
CLUSTER 4 2.48 (0.84–7.30) 0.1003 2.53 (0.85–7.52) 0.0944 3.04 (0.69–13.41) 0.1427 




Adjusted for matching variables. 
c 
Adjusted for matching variables and CVD risk factors. 
Discussion 
In this study, we examined the association between DNA-methylation and B-vitamins intake in relation to 
MI risk, focusing on the risk-effect of DNA-methylation profiles of 33 genes involved in Hcy and OCM 
pathways. 
We ascertained a lower intake of folic acid, pyridoxine, riboflavin and niacin both in male and female MI 
cases, and a general inverse relationship between B-vitamins intake and DNA-methylation of genes in OCM 
and Hcy pathways, in agreement with previous studies [10]. The analyses of anthropometric and lifestyle 
data showed statistically significant differences between cases and controls for known CVD risk factors, 
such as smoking status, alcohol and coffee consumption, obesity indices, blood pressure and lipids levels. 
We identified five significant DMRs (cases vs. controls), always with higher DNA-methylation in cases: TCN2 
and AMT methylation profiles were significant in males only, PON1 in females only, while, interestingly 
enough, CBS gene was found differentially methylated both in males and females. 
A significant inverse correlation between DNA-methylation of the identified DMRs and gene-expression 
levels was assessed in several tissues through data mining. A similar scenario can be speculated for blood-
derived DNA, suggesting a putative decrease of gene expression in MI cases, that who consistently display a 
higher DNA-methylation. The gene-functions also support the hypothesis of a CVD risk conferred by a lower 
gene expression in cases compared to controls. 
CBS activity in the trans-sulfuration pathway is known to mediate the balance between the 
hyperomocysteinemia-driven vascular damage and the production of the beneficial hydrogen sulphide 
(H2S), which proved effective in free radical scavenging, inflammation suppression and endothelial 
protection [15]. The minor allele of a polymorphism within the promoter of CBS gene was recently 
associated with promoter hypo-methylation and a marked increase in CBS transcription, putatively 
conferring protection due to low levels of Hcy maintained by CBS activity [16]. 
Although genetic variation was extensively investigated in the PON1 gene, involved in the prevention of LDL 
lipid peroxidation, no clear conclusion was drawn on the effect of genetic polymorphisms on the onset of 
Coronary Heart Disease (CHD), while it was suggested that PON1 activity and concentration may instead 
play a major role determining CHD [17]. On the same line, a recent extensive literature survey and pooled 
analysis highlighted that decreased PON1 activity was significantly associated with CHD risk [18]. 
Deleterious genetic variants in TCN2 gene, involved in vitamin B12 metabolism, were suggested to further 
aggravate the effects of low vitamin B12 levels and consequently high Hcy plasma concentrations, even if 
with contrasting results [19] and [20], while haplotypes in TCN2 were associated with premature ischemic 
stroke [21]. 
Concerning AMT gene, genetic variants were associated with glycine encephalopathy [22] and neural tube 
defects [23], but no evidence of its involvement in the onset of CVD was described up to now. 
Applying a RPMM cluster algorithm, we showed that different methylation profiles are associated to 
different MI risks, both in males and in females, and the effect is independent from the classical CVD risk 
factors. This model has been successfully used previously in other studies [24] and proved to be an efficient 
strategy for the analysis of methylation data derived by Illumina technology [25]. Notably, the methylation 
profiles of the above mentioned genes are still statistically significant risk factor also after adjusting for B-
vitamins intake, matching variables and other CVD risk factors. 
Conclusions and future directions 
Our findings further support the hypothesis that DNA-methylation of specific regions of genes involved in 
OCM and Hcy metabolic pathways can be a mediator of the CVD risk conferred by low B-vitamins intake. 
To understand if supplementation of B-vitamins in high risk subjects may be effective in preventing CVD, 
further investigations are needed to evaluate the effects of the interaction between B-vitamins intake and 
other exposures, such as smoking status or alcohol consumption, on DNA-methylation. 
Limitations of the study 
Notwithstanding our study had the power to detect only large differences at a single CpG level between 
cases and controls, the DMRs identified were statistically robust and consistent because discovered in a 
training set and validated in a test set. Despite we investigated the relationship between DNA-methylation 
and gene-expression in several tissues using publicly available datasets, no data are currently available on 
blood. Further investigations are needed to confirm that the inverse relationship observed in different 
tissues can be extended to blood. 
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